Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours (TA1034)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 January 2025
Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 26 June 2019Published: 24 September 2014
Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (TA323)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 November 2014
Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 October 2012
Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC